PFG Investments LLC Has $2.82 Million Stake in Bristol Myers Squibb Company $BMY

Posted by Stanley Muller on Jul 5th, 2026

PFG Investments LLC decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 18.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,436 shares of the biopharmaceutical company’s stock after selling 10,347 shares during the period. PFG Investments LLC’s holdings in Bristol Myers Squibb were worth $2,816,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Swiss RE Ltd. bought a new position in Bristol Myers Squibb in the fourth quarter worth approximately $25,000. Physician Wealth Advisors Inc. boosted its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the second quarter worth about $25,000. Bayban bought a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at $32,000. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of research reports. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Bank of America lowered their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.31.

View Our Latest Research Report on Bristol Myers Squibb

Bristol Myers Squibb Trading Down 0.1%

NYSE:BMY opened at $58.05 on Friday. The firm has a market capitalization of $118.54 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.17 and a beta of 0.23. The company has a fifty day moving average of $56.90 and a 200 day moving average of $57.49. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same period last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.